References
- 1. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005;85:1-31. doi: 10.1152/physrev.00048.2003.10.1152/physrev.00048.2003
- 2. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90:520-30. doi: 10.1161/01.res.0000013290.12884.a3.10.1161/01.RES.0000013290.12884.A3
- 3. Shah PK. Inflammation, metalloproteinases, and increased proteolysis: an emerging pathophysiological paradigm in aortic aneurysm. Circulation. 1997;96:2115-2117. doi: 10.1161/01.cir.96.7.2115.10.1161/01.CIR.96.7.2115
- 4. Ho-Tin-Noé B, Michel JB. Initiation of angiogenesis in atherosclerosis: smooth muscle cells as mediators of the angiogenic response to atheroma formation. Trends Cardiovasc Med. 2011;21:183-187. doi: 10.1016/j.tcm.2012.05.007.10.1016/j.tcm.2012.05.007
- 5. Kaperonis EA, Liapis CD, Kakisis JD, Dimitroulis D, Papavassiliou VG. Inflammation and atherosclerosis. Eur J Vasc Endovasc Surg. 2006;31:386-393. doi: 10.1016/j. ejvs.2005.11.001.
- 6. Bäck M, Ketelhuth DF, Agewall S. Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis. 2010;52:410-428. doi: 10.1016/j.pcad.2009.12.00210.1016/j.pcad.2009.12.002
- 7. Yabluchanskiy A, Ma Y, Iyer RP, Hall ME, Lindsey ML. Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. Physiology. 2013;28:391–403. doi: 10.1152/physiol.00029.2013.10.1152/physiol.00029.2013
- 8. Marino-Puertas L, Goulas T, Gomis-Rüth FX. Matrix metalloproteinases outside vertebrates. Biochim Biophys Acta Mol Cell Res. 2017;1864:2026-2035. doi: 10.1016/j. bbamcr.2017.04.003.
- 9. Benjamin MM, Khalil RA. Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. Exp Suppl. 2012;103:209-279. doi: 10.1007/978-3-0348-0364-9_7.10.1007/978-3-0348-0364-9_7
- 10. Olejarz W, Łacheta D, Kubiak-Tomaszewska G. Matrix Metalloproteinases as Biomarkers of Atherosclerotic Plaque Instability. Int J Mol Sci. 2020;21:3946. doi: 10.3390/ijms21113946.10.3390/ijms21113946
- 11. Borkakoti N. Structural studies of matrix metalloproteinases. J Mol Med. 2000;78:261–268. doi: 10.1007/s001090000113.10.1007/s001090000113
- 12. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000;102:1944-1949. doi: 10.1161/01. cir.102.16.1944.
- 13. Stewart JA Jr, Wei CC, Brower GL, Rynders PE, Hankes GH, Dillon AR, Lucchesi PA, Janicki JS, Dell’Italia LJ. Cardiac mast cell- and chymase-mediated matrix metalloproteinase activity and left ventricular remodeling in mitral regurgitation in the dog. J Mol Cell Cardiol. 2003;35:311-319. doi: 10.1016/s0022-2828(03)00013-0.10.1016/S0022-2828(03)00013-0
- 14. Liu P, Sun M, Sader S. Matrix metalloproteinases in cardiovascular disease. Can J Cardiol. 2006;22 Suppl B:25B-30B. doi: 10.1016/s0828-282x(06)70983-7.10.1016/S0828-282X(06)70983-7
- 15. Ehrmann M, Clausen T. Proteolysis as a regulatory mechanism. Annu Rev Genet. 2004;38:709-24. doi: 10.1146/annurev. genet.38.072902.093416.
- 16. Lambert E, Dassé E, Haye B, Petitfrère E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol. 2004;49:187-98. doi: 10.1016/j.critrevonc.2003.09.008.10.1016/j.critrevonc.2003.09.008
- 17. Simon F, Bergeron D, Larochelle S, Lopez-Vallé CA, Genest H, Armour A, Moulin VJ. Enhanced secretion of TIMP-1 by human hypertrophic scar keratinocytes could contribute to fibrosis. Burns. 2012;38:421-427. doi: 10.1016/j.burns.2011.09.001.10.1016/j.burns.2011.09.001
- 18. Swiderski RE, Dencoff JE, Floerchinger CS, Shapiro SD, Hunninghake GW. Differential expression of extracellular matrix remodeling genes in a murine model of bleomycin-induced pulmonary fibrosis. Am J Pathol. 1998;152:821-828.
- 19. McLennan SV, Wang XY, Moreno V, Yue DK, Twigg SM. Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy. Endocrinology. 2004;145:5646-5655. doi: 10.1210/en.2004-0436.10.1210/en.2004-0436
- 20. Knight BE, Kozlowski N, Havelin J, et al. TIMP-1 Attenuates the Development of Inflammatory Pain Through MMP-Dependent and Receptor-Mediated Cell Signaling Mechanisms. Front Mol Neurosci. 2019;12:220. doi: 10.3389/fnmol.2019.00220.10.3389/fnmol.2019.00220
- 21. Arpino V, Brock M, Gill SE. The role of TIMPs in regulation of extracellular matrix proteolysis. Matrix Biol. 2015;44-46:247-54. doi: 10.1016/j.matbio.2015.03.005.10.1016/j.matbio.2015.03.005
- 22. Gill SE, Pape MC, Khokha R, Watson AJ, Leco KJ. A null mutation for tissue inhibitor of metalloproteinases-3 (Timp-3) impairs murine bronchiole branching morphogenesis. Dev Biol. 2003;261:313-323. doi: 10.1016/s0012-1606(03)00318-x.10.1016/S0012-1606(03)00318-X
- 23. Gill SE, Pape MC, Leco KJ. Tissue inhibitor of metalloproteinases 3 regulates extracellular matrix--cell signaling during bronchiole branching morphogenesis. Dev Biol. 2006;298:540-554. doi: 10.1016/j.ydbio.2006.07.004.10.1016/j.ydbio.2006.07.00416890932
- 24. Tian H, Cimini M, Fedak PW, Altamentova S, Fazel S, Huang ML, Weisel RD, Li RK. TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction. J Mol Cell Cardiol. 2007;43:733-743. doi: 10.1016/j.yjmcc.2007.09.003.10.1016/j.yjmcc.2007.09.00317945252
- 25. Basu R, Lee J, Morton JS, Takawale A, Fan D, Kandalam V, Wang X, Davidge ST, Kassiri Z. TIMP3 is the primary TIMP to regulate agonist-induced vascular remodelling and hypertension. Cardiovasc Res. 2013;98:360-371. doi: 10.1093/cvr/cvt067.10.1093/cvr/cvt06723524300
- 26. Takawale A, Fan D, Basu R, Shen M, Parajuli N, Wang W, Wang X, Oudit GY, Kassiri Z. Myocardial recovery from ischemiareperfusion is compromised in the absence of tissue inhibitor of metalloproteinase 4. Circ Heart Fail. 2014;7:652-662. doi: 10.1161/CIRCHEARTFAILURE.114.001113.10.1161/CIRCHEARTFAILURE.114.00111324842912
- 27. Watanabe-Takano H, Takano K, Sakamoto A, et al. DA-Raf-dependent inhibition of the Ras-ERK signaling pathway in type 2 alveolar epithelial cells controls alveolar formation. Proc Natl Acad Sci U S A. 2014;111:E2291-300. doi: 10.1073/pnas.1321574111.10.1073/pnas.1321574111405057824843139
- 28. Shynlova O, Bortolini MAT, Alarab M. Genes responsible for vaginal extracellular matrix metabolism are modulated by women’s reproductive cycle and menopause. International Braz J Urol. 2013;39:257-267. doi: 10.1590/S1677-5538. IBJU.2013.02.15
- 29. Kyle DJ, Harvey AG, Shih B, Tan KT, Chaudhry IH, Bayat A. Identification of molecular phenotypic descriptors of breast capsular contracture formation using informatics analysis of the whole genome transcriptome. Wound Repair Regen. 2013;21:762-769. doi: 10.1111/wrr.12077.10.1111/wrr.1207723941504
- 30. Magdalena K, Magdalena K, Grazyna S. The Role of Matrix Metalloproteinase-3 In the Development of Atherosclerosis and Cardiovascular Events. EJIFCC. 2006;17:2-5.
- 31. Yoon YW, Kwon HM, Hwang KC, et al. Upstream regulation of matrix metalloproteinase by EMMPRIN; extracellular matrix metalloproteinase inducer in advanced atherosclerotic plaque. Atherosclerosis. 2005;180:37-44. doi: 10.1016/j. atherosclerosis.2004.11.021.
- 32. Wang X, Khalil RA. Matrix metalloproteinases, vascular remodeling, and vascular disease. Adv. Pharmacol. 2018;81:241–330. doi: 10.1016/bs.apha.2017.08.002.10.1016/bs.apha.2017.08.002576587529310800
- 33. Kowara M, Cudnoch-Jedrzejewska A, Opolski G, Wlodarski P. MicroRNA regulation of extracellular matrix components in the process of atherosclerotic plaque destabilization. Clin. Exp. Pharmacol. Physiol. 2017;44:711–718. doi: 10.1111/1440-1681.12772.10.1111/1440-1681.1277228440887
- 34. Newby AC. Metalloproteinase production from macrophages—A perfect storm leading to atherosclerotic plaque rupture and myocardial infarction. Exp. Physiol. 2016;101:1327–1337. doi: 10.1113/EP085567.10.1113/EP08556726969796
- 35. Chen Q, Wang Q, Zhu J, Xiao Q, Zhang L. Reactive oxygen species: Key regulators in vascular health and diseases. Br. J. Pharmacol. 2018;175:1279–1292. doi: 10.1111/bph.13828.10.1111/bph.13828586702628430357
- 36. Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler. Thromb. Vasc. Biol. 2008;28:2108– 2114. doi: 10.1161/ATVBAHA.108.173898.10.1161/ATVBAHA.108.17389818772495
- 37. Amato B, Compagna R, Amato M, et al. Adult vascular wall resident multipotent vascular stem cells, matrix metalloproteinases, and arterial aneurysms. Stem Cells Int. 2015;2015:434962. doi: 10.1155/2015/434962.10.1155/2015/434962438185225866513
- 38. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 2004;16:558–564. doi: 10.1016/j.ceb.2004.07.010.10.1016/j.ceb.2004.07.010277544615363807
- 39. Chistiakov DA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN. Calcifying matrix vesicles and atherosclerosis. Biomed. Res. Int. 2017;2017:7463590. doi: 10.1155/2017/7463590.10.1155/2017/7463590569739229238720
- 40. Gaubatz JW, Ballantyne CM, Wasserman BA, et al. Association of circulating matrix metalloproteinases with carotid artery characteristics: The atherosclerosis risk in communities carotid mri study. Arterioscler Thromb. Vasc Biol. 2010;30:1034–1042. doi: 10.1161/ATVBAHA.109.195370.10.1161/ATVBAHA.109.195370286038320167662
- 41. Sasaki T, Nakamura K, Sasada K, et al. Matrix metalloproteinase-2 deficiency impairs aortic atherosclerotic calcification in apoE-deficient mice. Atherosclerosis. 2013;227:43–50. doi: 10.1016/j.atherosclerosis.2012.12.008.10.1016/j.atherosclerosis.2012.12.00823312504
- 42. Purroy A, Roncal C, Orbe J, et al. Matrix metalloproteinase-10 deficiency delays atherosclerosis progression and plaque calcification. Atherosclerosis. 2018;278:124–134. doi: 10.1016/j. atherosclerosis.2018.09.022.
- 43. Loftus IM, Naylor AR, Bell PR, Thompson MM. Matrix metalloproteinases and atherosclerotic plaque instability. Br. J. Surg. 2002;89:680-694. doi: 10.1046/j.1365-2168.2002.02099.x.10.1046/j.1365-2168.2002.02099.x12027977
- 44. Myasoedova VA, Chistiakov DA, Grechko AV, Orekhov AN. Matrix metalloproteinases in pro-atherosclerotic arterial remodeling. J. Mol. Cell Cardiol. 2018;123:159–167. doi: 10.1016/j.yjmcc.2018.08.026.10.1016/j.yjmcc.2018.08.02630172754
- 45. Lahdentausta L, Leskelä J, Winkelmann A, et al. Serum MMP-9 Diagnostics, Prognostics, and Activation in Acute Coronary Syndrome and Its Recurrence. J Cardiovasc Transl Res. 2018;11:210-220. doi: 10.1007/s12265-018-9789-x.10.1007/s12265-018-9789-x597400129349668
- 46. Li T, Li X, Feng Y, Dong G, Wang Y, Yang J. The Role of Matrix Metalloproteinase-9 in Atherosclerotic Plaque Instability. Mediators Inflamm. 2020;2020:3872367. doi: 10.1155/2020/3872367.10.1155/2020/3872367755789633082709
- 47. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503. doi: 10.1172/JCI117619.10.1172/JCI1176193300837989608
- 48. Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med. 2001;345:1022-1029. doi: 10.1056/NEJMoa003147.10.1056/NEJMoa00314711586954
- 49. Noji Y, Kajinami K, Kawashiri MA, et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med. 2001;39:380-384. doi: 10.1515/CCLM.2001.060.10.1515/CCLM.2001.06011434385
- 50. Pleva L, Kusnierova P, Plevova P, et al. Increased levels of MMP-3, MMP-9 and MPO represent predictors of in-stent restenosis, while increased levels of ADMA, LCAT, ApoE and ApoD predict bare metal stent patency. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159:586-594. doi: 10.5507/bp.2015.037.10.5507/bp.2015.037
- 51. Katsaros K, Kastl SP, Zorn G, et al. Increased Restenosis Rate After Implantation of Drug-Eluting Stents in Patients With Elevated Serum Activity of Matrix Metalloproteinase-2 and -9. JACC: Cardiovascular Interventions. 2010;3:90-97. doi: 10.1016/j.jcin.2009.10.023.10.1016/j.jcin.2009.10.023
- 52. Orbe J, Fernandez L, Rodríguez JA, et al. Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis. 2003;170:269-276. doi: 10.1016/s0021-9150(03)00251-x.10.1016/S0021-9150(03)00251-X
- 53. Knox JB, Sukhova GK, Whittemore AD, Libby P. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation. 1997;95:205-212. doi: 10.1161/01.cir.95.1.205.10.1161/01.CIR.95.1.205
- 54. Ruddy JM, Ikonomidis JS, Jones JA. Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability. J Vasc Res. 2016;53:1-16. doi. org/10.1159/000446703.10.1159/000446703719692627327039
- 55. Johnson J, Jenkins N, Huang W et al. Relationship of MMP-14 and TIMP-3 Expression with Macrophage Activation and Human Atherosclerotic Plaque Vulnerability. Mediators of Inflammation. 2014;2014;1-17. doi: 10.1155/2014/276457.10.1155/2014/276457416318625301980
- 56. Lee JK, Zaidi SH, Liu P, Dawood F, Cheah AY, Wen WH, Saiki Y, Rabinovitch M. A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced murine myocarditis. Nat Med. 1998;4:1383-1391. doi: 10.1038/3973.10.1038/39739846575
- 57. Fukuda D, Shimada K, Tanaka A, et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol. 2006;97:175-180. doi: 10.1016/j.amjcard.2005.08.020.10.1016/j.amjcard.2005.08.02016442358
- 58. Kobayashi N, Hata N, Kume N, et al. Matrix metalloproteinase-9 for the earliest stage acute coronary syndrome. Circ J. 2011;75:2853-2861. doi: 10.1253/circj.cj-11-0640.10.1253/circj.CJ-11-0640
- 59. Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ. Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem. 1996;155:13-21. doi: 10.1007/BF00714328.10.1007/BF007143288717434
- 60. Sun M, Dawood F, Wen WH, et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation. 2004;110:3221-3228. doi: 10.1161/01. CIR.0000147233.10318.23.
- 61. Kelly D, Khan SQ, Thompson M, et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodeling and prognosis after acute myocardial infarction. Eur Heart J. 2008;29:2116-2124. doi: 10.1093/eurheartj/ehn315.10.1093/eurheartj/ehn315294171718614523
- 62. Van Doren SR. Matrix metalloproteinase interactions with collagen and elastin. Matrix Biol. 2015;44-46:224-231. doi: 10.1016/j.matbio.2015.01.005.10.1016/j.matbio.2015.01.005446614325599938
- 63. Zhou ZX, Qiang H, Ma AQ, Chen H, Zhou P. Measurement peripheral blood index related to inflammation and ox-LDL, ox-LDLAb in patients with coronary heart disease and its clinical significance. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006;31:258-262.
- 64. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J. 2001;141:211-217. doi: 10.1067/mhj.2001.112238.10.1067/mhj.2001.11223811174334
- 65. Kumpatla S, Karuppiah K, Immaneni S, et al. Comparison of plasma adiponectin & certain inflammatory markers in angiographically proven coronary artery disease patients with & without diabetes – a study from India. Indian J Med Res. 2014;139:841-850.
- 66. Hamed GM, Fattah MF. Clinical Relevance of matrix metalloproteinase 9 in patients with acute coronary syndrome. Clin Appl Thromb Hemost. 2015;21:705-711. doi: 10.1177/1076029614567309.10.1177/107602961456730925616488
- 67. Owolabi US, Amraotkar AR, Coulter AR, et al. Change in matrix metalloproteinase 2, 3, and 9 levels at the time of and after acute atherothrombotic myocardial infarction. J Thromb Thrombolysis. 2020;49:235-244. doi: 10.1007/s11239-019-02004-7.10.1007/s11239-019-02004-7901298231808123
- 68. Opstad TB, Seljeflot I, Bøhmer E, Arnesen H, Halvorsen S. MMP-9 and Its Regulators TIMP-1 and EMMPRIN in Patients with Acute ST-Elevation Myocardial Infarction: A NORDISTEMI Substudy. Cardiology. 2018;139:17-24. doi: 10.1159/000481684.10.1159/00048168429141241
- 69. Zhu JJ, Zhao Q, Qu HJ, et al. Usefulness of plasma matrix metalloproteinase-9 levels in prediction of in-hospital mortality in patients who received emergent percutaneous coronary artery intervention following myocardial infarction. Oncotarget. 2017;8:105809-105818. doi: 10.18632/oncotarget.22401.10.18632/oncotarget.22401573968129285294
- 70. Dhillon OS, Khan SQ, Narayan HK, et al. Matrix metalloproteinase-2 predicts mortality in patients with acute coronary syndrome. Clin Sci (Lond). 2009;118:249-257. doi: 10.1042/CS20090226.10.1042/CS2009022619583569
- 71. Wu TC, Leu HB, Lin WT, Lin CP, Lin SJ, Chen JW. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease. Eur J Clin Invest. 2005;35:537-545. doi: 10.1111/j.1365-2362.2005.01548.x.10.1111/j.1365-2362.2005.01548.x16128859